Blanket Purchase Agreement V797D50492-36E79720A0014

The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for hereditary angioedema, GATTEX for short bowel syndrome, and NATPARA for hypocalcemia. This 4-year agreement enables the VA to efficiently order these specialized treatments, ensuring consistent access for eligible veteran patients. As a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America Inc. primarily supplies specialty drugs to various U.S. government agencies, including the Department of Veterans Affairs, Department of Justice Bureau of Prisons, and Department of Defense. The company leverages its parent's international infrastructure to deliver these critical medications to federal facilities nationwide.